SEC Form 4 · accession 0001209191-16-121285
ReShape Lifesciences Inc. · RSLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dan W Gladney
Officer — Chief Executive Officer · Director
Period of report
May 16, 2016
Accepted (ET)
May 18, 2016 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 16, 2015 | P | 84,745 | $0.7232 | A | 134,745 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $3.75 | holding | — | — | — | Oct 28, 2016 | Oct 28, 2025 | Common Stock | 516,666 | 516,666 | D |
Explanation of responses
- F1On January 6, 2016, EnteroMedics Inc. effected a 1-for-15 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
- F2Vests as to 25% one year from the date of the employment agreement on the date noted and thereafter in cumulative installments of 1/36th per month.